The Filing Desk

iRhythm

IRTC · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

IRTC · Last close · November 13, 2026
$91.91
Value iRhythm yourself

iRhythm's revenue rose 26.2% to $747 million in fiscal 2025. Its operating margin was −7.7%, up from −19.5% a year earlier. Free cash flow was $35 million. The diluted share count rose 2.6%.

iRhythm Holdings, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 19, 2026 · 0001388658-26-000011 Updated
Revenue
$747M
26.2%
Operating margin
−7.7%
11.8 pts
Net income
−$45M
 
Free cash flow
$35M
 
Return on capital
−12.4%
20.5 pts
Market cap
$3.0B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What iRhythm does

iRhythm provides heart-rhythm monitoring services. Its main product is a wire-free patch that a patient wears on the chest. The patch is worn for up to 14 days and records the heart's electrical signals continuously. The recordings are analyzed by the company's cloud-based software, and its technicians then prepare reports for doctors. Doctors use them to diagnose arrhythmias, which are irregular heartbeats.

iRhythm's services include long-term continuous monitoring, short-term monitoring and mobile cardiac telemetry. These are usually ordered for patients who are suspected of having infrequent, hard-to-detect or symptom-free arrhythmias, but not life-threatening ones. iRhythm provides these services from its own testing facilities, which are enrolled in Medicare.

The services are currently its only offerings, and its revenue depends on insurers and government programs paying for them. The company says its patch and software are cleared or approved in the United States, Europe and Japan. It employs about 2,400 full-time employees.

Its biggest risks, as it describes them

  • Reimbursement for its services could be reduced or changed in the United States or in other countries.
  • It may not be able to add commercial payors or expand coverage from the ones it has.
  • Its revenue relies entirely on its iRhythm Services, which could lose market acceptance.
  • Billing is complex and highly regulated, and audits or denied claims could force it to pay money back.
  • Competition in remote cardiac monitoring is intense.
From iRhythm's annual report on Form 10-K, filed February 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

iRhythm lost money in fiscal 2025: a net loss of $45 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments222159110317490
Debt incl. finance leases103535646650
Net debt (negative means net cash)−212−124−75329159
Net debt to EBITDA—————
Debt to equity0.0x0.1x0.2x7.1x4.2x
Interest coverage−85.5x−27.5x−34.3x−9.0x−4.4x
Current ratio3.5x3.2x2.1x5.8x4.6x
Quick ratio3.4x3.1x2.0x5.7x4.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project iRhythm's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What iRhythm says to expect

  • Full year 2026: revenue and adjusted EBITDA marginFor the full year 2026, iRhythm expects revenue between $890 million and $895 million, which includes approximately $16 million of expected VitalConnect revenue contribution from the October 5, 2026 acquisition close through year-end. iRhythm also expects adjusted EBITDA margin between 15.5% and 16.0%, inclusive of VitalConnect.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $56,892 of iRhythm shares on the open market, and 12 insiders sold $22.7 million, $1.9 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 2, 2026Daniel G. WilsonChief Financial OfficerSold773$121.83$94,175Form 4
Aug 10, 2026Quentin S. BlackfordPresident and CEO, DirectorSold26,859$124.65$3.3 millionForm 4
Aug 10, 2026Patrick Michael MurphyCBO and CLOSold7,093$124.65$884,142Form 4
Aug 10, 2026Sumi ShrishrimalEVP, Chief Risk OfficerSold5,372$124.65$669,620Form 4
Aug 3, 2026Chad PattersonChief Comm & Product OfficerSold2,712$122.12$331,189Form 4
Aug 3, 2026Julianne RoddaEVP, Chief People OfficerSold2,112$122.12$257,917Form 4
Aug 3, 2026Mervin SmithEVP Strategic Business OpsSold617$122.12$75,348Form 4
Jul 2, 2026Minang TurakhiaChief Med/sci Ofcr EVP AdvtechSold1,423$124.71$177,462Form 4
Jul 2, 2026Sean Clinton FreemanEVP, Strategy & Corp DevtSold918$124.71$114,484Form 4
Jun 2, 2026Sumi ShrishrimalEVP, Chief Risk OfficerSold1,716$108.19$185,654Form 4
Jun 2, 2026Marc Wade RosenbaumChief Accounting OfficerSold729$108.19$78,871Form 4
May 11, 2026Abhijit Y TalwalkarDirectorSold plan5,312$117.93$626,438Form 4
The latest 12 of 36 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 96 of 95 of 9
Rule of 401.5%15.0%30.9%
Altman Z''−3.940.390.78
Accruals ratio−16.6%−17.1%−12.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailPass
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassFail
F-score2 of 96 of 95 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put iRhythm side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
iRhythmFY2526.2%−7.7%4.6%−12.4%—5
AlphatecFY2524.9%−10.8%0.4%−14.3%—5Compare
Varex ImagingFY254.1%−3.3%2.2%−2.9%—6Compare
NovocureFY258.3%−23.5%−11.6%−33.0%—4Compare
Inspire Medical SystemsFY2513.6%5.6%8.6%14.2%−4.8x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue6499147215265323411493592747
Revenue growth77.3%54.7%48.6%45.7%23.6%21.7%27.3%19.9%20.1%26.2%
Gross profit4371108162195214282332408527
Research and development7132137413947607285
Operating income−16−28−46−55−44−100−114−125−116−57
Net income−21−30−50−55−44−101−116−123−113−45
Diluted EPS (US$)−3.95−1.31−2.11−2.16−1.58−3.46−3.88−4.04−3.63−1.39
Diluted shares (millions)5232425282930303132
Cash flow
Cash from operations−17−15−29−22−14−38−23−50381
Capital expenditure34520142830403446
Free cash flow−19−18−34−42−27−66−53−91−3135
Dividends paid0000000000
Share buybacks00000000250
Acquisitions0000000000
Stock-based compensation2101626425458777688
Balance sheet at fiscal year end
Cash and short-term investments11110278141335222159110317490
Debt incl. finance leases4645353321103535646650
Total assets1381331183065124634484339311,020
Total liabilities465465171170184208223840867
Shareholders' equity93795213534228024021091153
Margins and ratios
Gross margin67.4%71.5%73.7%75.5%73.5%66.2%68.5%67.3%68.9%70.6%
Operating margin−24.3%−27.8%−31.0%−25.5%−16.5%−31.0%−27.7%−25.4%−19.5%−7.7%
Net margin−32.6%−30.0%−34.2%−25.4%−16.5%−31.4%−28.3%−25.1%−19.1%−6.0%
Free cash flow margin−30.3%−18.6%−23.3%−19.7%−10.3%−20.4%−12.9%−18.4%−5.2%4.6%
Rule of 40 (growth + FCF margin)47.0%36.1%25.3%25.9%13.3%1.4%14.4%1.5%15.0%30.9%
Return on capital—−87.5%−237.1%———−97.9%−78.8%−32.9%−12.4%
Return on equity—−34.5%−76.6%−58.2%−18.4%−32.6%−44.7%−54.9%−75.3%−36.6%
Return on assets−23.8%−21.9%−40.2%−25.8%−10.7%−20.8%−25.5%−28.0%−16.6%−4.6%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: iRhythm's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with iRhythm.